Elekta’s Q1 results showed resilience in challenging market conditions. While the top-line benefited from higher service revenue and double-digit growth in China, profitability outperformance was driven by a favourable product mix and strict cost management. Importantly, in the weak radiotherapy market, gross order intake was in the black on the back of a big order from GenesisCare in the US. With Unity now in the growth phase of commercialisation and a new linac around the corner, Elek
![working](/images/WorkingLarge.gif)
26 Aug 2020
High-margin service revenue and China led to outperformance in Q1
![](/images/orange-lock.png)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
High-margin service revenue and China led to outperformance in Q1
Elekta AB Class B (EJXB:FRA) | 0 0 0.5% | Mkt Cap: 27,040m
- Published:
26 Aug 2020 -
Author:
Sumit Sayal -
Pages:
4 -
Elekta’s Q1 results showed resilience in challenging market conditions. While the top-line benefited from higher service revenue and double-digit growth in China, profitability outperformance was driven by a favourable product mix and strict cost management. Importantly, in the weak radiotherapy market, gross order intake was in the black on the back of a big order from GenesisCare in the US. With Unity now in the growth phase of commercialisation and a new linac around the corner, Elek